Jeevan Scientific Q1 FY27 Results: Revenue More Than Doubles to Rs 18 Crore, Turns Profitable at Rs 88 Lakh
- August 14, 2026
- Posted by: Lakshit Sharma
- Category: Market
Jeevan Scientific Q1 FY27: Revenue Rs 18 Cr (+107.72% YoY). PAT Rs 0.88 Cr vs loss Rs 3 Cr. Gross profit Rs 1 Cr vs Rs -3 Cr. CMP Rs 83.33 on Aug 13.
Quick Answer
Jeevan Scientific delivered a transformational Q1 FY27 performance, with consolidated revenue more than doubling to Rs 18 crore from Rs 8 crore in Q1 FY26. PAT swung to a profit of Rs 0.88 crore from a loss of Rs 3 crore, and gross profit turned positive at Rs 1 crore from Rs -3 crore. Jeevan Scientific Q1 FY27 results represent a meaningful operational turnaround for the CRO and clinical research services company.
Jeevan Scientific Q1 FY27 results showed the Hyderabad-based contract research organisation (CRO) delivering a 107.72% revenue surge to Rs 18 crore from Rs 8 crore in Q1 FY26 on a consolidated basis. The doubling of revenue reflects either significant new clinical trial contracts, expansion of the company’s bioequivalence and bioanalytical services, or new pharmaceutical customer additions.
The Jeevan Scientific Q1 FY27 results showed gross profit swinging dramatically from Rs -3 crore to Rs 1 crore alongside the revenue doubling. Net profit turned positive at Rs 0.88 crore from a loss of Rs 3 crore in Q1 FY26. This turnaround reflects the operating leverage of the CRO business model, where once revenue reaches sufficient scale to cover fixed laboratory and employee costs, the incremental revenue flows rapidly to profitability.
Click Here – Get Free Investment Predictions
Jeevan Scient Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Crore) | Q1 FY26 (Rs Crore) | YoY Change |
|---|---|---|---|
| Revenue | 18.00 | 8.00 | +107.72% |
| Gross Profit | 1.00 | -3.00 | +135.46% |
| Net Profit / PAT | 0.88 | -3.00 | +127.23% |
Jeevan Scient Q1 FY27 Performance Analysis
Use the Univest Screener to track Jeevan Scient live financials and Q1 FY27 results
Jeevan Scientific Q1 FY27 results represent a significant inflection point for the company. Revenue doubling from Rs 8 crore to Rs 18 crore has crossed the operating breakeven threshold, turning the business from deeply loss-making to marginally profitable. For CRO businesses with high fixed laboratory infrastructure and skilled scientist costs, revenue scaling to cover these fixed costs is the critical milestone.
The gross profit swing in Jeevan Scientific Q1 FY27 results from Rs -3 crore to Rs 1 crore on Rs 10 crore of additional revenue implies a gross contribution rate of approximately 40% on the incremental revenue. This is consistent with CRO businesses where additional clinical studies can be accommodated within the existing laboratory capacity without proportionate cost increases.
The PAT of Rs 0.88 crore in Jeevan Scientific Q1 FY27 results, swinging from a loss of Rs 3 crore, is modest in absolute terms but represents a Rs 3.88 crore improvement — highly meaningful for a company of this scale. Sustaining and growing this profit will require continued revenue scaling through new clinical trial mandates.
Jeevan Scientific Q1 FY27 results suggest the company has successfully expanded its CRO service portfolio and customer base to achieve revenue scale. The pharmaceutical sector’s growing R&D spending, particularly in generics for regulated markets, provides a structural demand tailwind for quality Indian CROs.
Key Business Factors in Q1 FY27
Revenue Doubling Through CRO Growth
The 108% revenue jump in Jeevan Scientific Q1 FY27 results from Rs 8 crore to Rs 18 crore reflects significant new clinical trial and research contract wins. Indian CROs are benefiting from global pharmaceutical companies’ increasing R&D outsourcing to cost-competitive Indian facilities.
Operating Leverage at CRO Scale
The gross profit swing from Rs -3 crore to Rs 1 crore on Rs 10 crore additional revenue in Jeevan Scientific Q1 FY27 results demonstrates the operating leverage inherent in laboratory-based research services. Once the capacity and scientist base is in place, incremental studies contribute significantly to profitability.
Pharmaceutical R&D Outsourcing
India’s CRO sector benefits from the global pharmaceutical industry’s increasing R&D outsourcing to India, driven by cost advantages and the availability of qualified clinical research professionals. Jeevan Scientific Q1 FY27 results reflect the company capturing this structural growth in the Indian CRO market.
Dividend Details
Jeevan Scientific has not declared a dividend for Q1 FY27. The company is in a growth and scaling phase in the CRO business, and earnings are expected to be reinvested in laboratory capacity and regulatory capabilities rather than distributed as dividends.
FY27 Outlook
The FY27 outlook for Jeevan Scientific is positive following the Q1 FY27 results turnaround. If the revenue momentum is sustained and the company continues to win new clinical trial mandates, operating leverage should continue to improve PAT through Q2 and Q3 FY27.
Key risks include the competitive landscape in Indian CROs, the lumpy nature of clinical trial project revenue, and any regulatory challenges from global health authorities that could delay approvals or reduce the attractiveness of Indian CRO studies for multinational pharmaceutical companies.
Jeevan Scient Stock Performance
Download the Univest iOS App or Univest Android App to track Jeevan Scient share price live and stay updated on quarterly results.
Jeevan Scientific shares traded at Rs 83.33 on August 13, 2026, up 6.13% on the day, reflecting strong market enthusiasm for the revenue doubling and PAT turnaround in Q1 FY27 results. The stock’s continued performance will depend on sustaining the revenue momentum through subsequent quarters.
Key Risks
Revenue Lumpiness in CRO Business
Clinical trial revenue in CRO businesses is project-based and can be lumpy. If Q1 FY27 results benefited from a particularly strong project delivery quarter, Q2 FY27 may see some moderation if new projects are not yet in the execution phase.
Regulatory and Compliance Risk
CRO businesses operate under strict regulatory oversight from CDSCO, FDA, and other global health authorities. Any compliance findings or warning letters could disrupt operations and reduce new mandate wins, impacting revenue from Q1 FY27 results levels.
Competition from Larger Indian CROs
The Indian CRO market includes well-established players like Syngene, Jubilant Biosys, and Divi’s Laboratories. Competing for complex global pharmaceutical mandates requires continuous investment in laboratory infrastructure, which could add to costs even as revenues scale.
Conclusion
Jeevan Scientific Q1 FY27 results represent a meaningful operational turnaround, with revenue more than doubling to Rs 18 crore and PAT swinging to Rs 0.88 crore from a loss of Rs 3 crore. The results validate the company’s scaling strategy in the growing Indian CRO sector.
Sustaining the revenue momentum and converting it to improving profitability will be the key test in Q2 and Q3 FY27. Investors should monitor new contract wins and regulatory compliance status alongside the Jeevan Scientific Q1 FY27 results trajectory. Consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Jeevan Scient Q1 FY27 Results
When were Jeevan Scientific Q1 FY27 results announced?
Ans. Jeevan Scientific Q1 FY27 results were announced on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was Jeevan Scientific’s revenue in Q1 FY27?
Ans. Jeevan Scientific reported consolidated revenue of Rs 18 crore in Q1 FY27, up 107.72% from Rs 8 crore in Q1 FY26.
Did Jeevan Scientific turn profitable in Q1 FY27?
Ans. Yes, Jeevan Scientific Q1 FY27 results show the company turning profitable with a net profit of Rs 0.88 crore, swinging from a loss of Rs 3 crore in Q1 FY26.
What drove Jeevan Scientific’s revenue to double in Q1 FY27?
Ans. Jeevan Scientific Q1 FY27 results reflect significant new CRO contract wins and scaling of clinical trial services. The global pharmaceutical industry’s increasing R&D outsourcing to India, combined with the company’s expanded capabilities, drove the revenue doubling.
Did Jeevan Scientific declare a dividend after Q1 FY27 results?
Ans. Jeevan Scientific has not declared a dividend for Q1 FY27. The company is reinvesting earnings in CRO capacity and business development.
What is the outlook for Jeevan Scientific after Q1 FY27 results?
Ans. The FY27 outlook is positive, supported by the structural growth in Indian CRO services. Sustaining the revenue momentum and managing project-level lumpiness will be key.
Is Jeevan Scientific a good investment after Q1 FY27 results?
Ans. Jeevan Scientific Q1 FY27 results show a meaningful turnaround with revenue doubling and PAT turning positive. Investors should assess new contract pipeline and regulatory standing before investing. Consult a SEBI-registered advisor.